CA-ARRCUS
26.2.2024 09:01:34 CET | Business Wire | Press release
Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, announces the enhancement of its ACE-AI platform to address the growing demand for unified networking fabric for distributed AI workloads.
As AI workloads become increasingly distributed, driven by economic considerations and application requirements, Arrcus ACE-AI is a platform designed to seamlessly network them across various locations and deliver applications at the edge, with high speed and lossless connectivity. The emerging federated learning model for AI allows multiple entities to collaboratively train a model with decentralized data. Training models may be executed in hyperscale environments while inference models may be executed at the edge for various use cases. Arrcus recognizes the need for a unified networking fabric that interconnects these workloads, regardless of where they may reside. Modern data center applications demand high throughput (400-800Gbps) and ultra-low latency (< 10μs per hop), and Arrcus ACE-AI meets these demands while minimizing CPU overhead.
"The future of AI lies in its ubiquity, and Arrcus has built the industry’s most flexible and intelligent fabric that connects and orchestrates distributed AI workloads,” said Shekar Ayyar, Chairman and CEO of Arrcus. “With the enhanced ACE-AI platform, we are giving enterprises and service providers the power to unlock the full potential of AI, across clouds, data centers, and the edge."
Emerging artificial intelligence, high-performance computing, and storage workloads pose new challenges for large-scale datacenter networking. Arrcus addresses these challenges by supporting new features that build a lossless Ethernet fabric, including RoCEv2, PFC, ECN, ETS, AR, Dynamic Load Balancing, and Global Load Balancing.
One of the significant challenges in achieving high-performance networking for AI workloads is the limitation of traditional TCP/IP stacks at such speeds due to their high CPU overhead. Arrcus addresses this challenge by incorporating RDMA (Remote Direct Memory Access) technology, which offloads transport communication tasks from the CPU to hardware, providing direct memory access for applications without involving the CPU. The second version of RDMA over Converged Ethernet (RoCE-v2) further enhances the protocol with UDP/IP headers with routing.
In addition to these feature enhancements, Arrcus is also pleased to announce support for new industry-leading platforms from Broadcom that are state-of-the-art 800G switching platforms – Tomahawk5, Jericho3, Ramon3 – in partnership with device manufacturers like Ufispace and Edgecore.
"Broadcom is very excited to collaborate with Arrcus to deliver industry-leading switching solutions that are optimized to meet the performance demands of next-generation AI workloads. Together, Arrcus and Broadcom are enabling customers to build high-performance, scalable, and intelligent data center networks,” said Ram Velaga, senior vice president and general manager, Core Switching Group, Broadcom.
Key features that make Arrcus the industry’s leading networking platform for AI:
- High-Performance Networking for AI: Support for industry-leading hardware with Broadcom switches like Tomahawk5 and Jericho3-AI, RoCEv2, SmartNICs from NVIDIA and Intel, and enabling ultra-low latency (< 10μs per hop) and high throughput (400-800Gbps) required by modern AI applications.
- Multi-Cloud Cost Optimization: Enhanced FlexMCN with Egress Cost Control (ECC) technology empowers users to analyze, allocate, and dynamically route traffic across clouds for optimal cost efficiency, reducing egress charges by up to 15%.
- Automated 5G Network Slicing for AI: Integration of SRv6 Mobile User Plane (MUP) and Flex Algo enables automated delivery of AI applications with 5G network slicing, streamlining service deployment and resource allocation.
- End-to-End Network Visibility with ArcIQ: New ArcIQ capabilities extend real-time network insights to user equipment, providing actionable data for proactive incident management.
With these latest capabilities and dedication to innovation, Arrcus is enabling organizations to break through the limitations of traditional networking and embrace the full potential of distributed AI. The enhanced ACE-AI platform signifies a pivotal step in building the intelligent fabric for the AI-powered future.
Additional Resources
- Arrcus Unveils Groundbreaking ACE-AI Networking Solution
- Arrcus Delivers Next Generation of High-Performance, Zero-Trust Networking for Datacenters Enabled by NVIDIA BlueField
About Arrcus
Arrcus was founded to enhance business efficiency through superior network connectivity. The Arrcus Connected Edge (ACE) platform offers best-in-class networking with the most flexible consumption model at the lowest total cost of ownership. The Arrcus team consists of world-class technologists who have an unparalleled record in shipping industry-leading networking products, complemented by industry thought leaders, operating executives, strategic partners and top-tier VCs. The company is headquartered in San Jose, California, with offices in Bangalore, India, and Tokyo, Japan. For more information, go to www.arrcus.com or follow @arrcusinc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226461853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
